22.626 articles found

The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.

Stocchi F.

Neurodegener Dis · 2010-03-12

DOI: 10.1159/000295667PMID: 20224289

Parkinson's disease: oxidative stress and therapeutic approaches.

Surendran S, Rajasankar S.

Neurol Sci · 2010-03-10

DOI: 10.1007/s10072-010-0245-1PMID: 20221655

THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN

KYLE DONALD J, SUN QUN.

· 2010-03-02

POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE

SMALL SCOTT A, LEWANDOWSKI NICOLE, LANDRY DONALD W, DENG SHI-XIANG.

· 2010-03-01

Stem cell therapy for Parkinson's disease: a road map for a successful future.

Vidaltamayo R, Bargas J, Covarrubias L, Hernández A, Galarraga E, Gutiérrez-Ospina G, Drucker-Colin R.

Stem Cells Dev · 2010-03-01

DOI: 10.1089/scd.2009.0205PMID: 19715418

Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study.

Zangaglia R, Stocchi F, Sciarretta M, Antonini A, Mancini F, Guidi M, Martignoni E, Pacchetti C.

Clin Neuropharmacol · 2010-03-01

DOI: 10.1097/wnf.0b013e3181c5e60cPMID: 19935405

Cell based-gene delivery approaches for the treatment of spinal cord injury and neurodegenerative disorders.

Taha MF.

Curr Stem Cell Res Ther · 2010-03-01

DOI: 10.2174/157488810790442778PMID: 19951254

NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.

Varanese S, Howard J, Di Rocco A.

Mov Disord · 2010-03-01

DOI: 10.1002/mds.22917PMID: 20014061

Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.

Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, Vives F.

Mov Disord · 2010-03-01

DOI: 10.1002/mds.22928PMID: 20063406

Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.

Sabens EA, Distler AM, Mieyal JJ.

Biochemistry · 2010-03-01

DOI: 10.1021/bi9018658PMID: 20141169

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Ghosh B, Antonio T, Reith ME, Dutta AK.

J Med Chem · 2010-03-01

DOI: 10.1021/jm901618dPMID: 20146482

Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.

Toth C, Suchowersky O, Zochodne D.

Mov Disord · 2010-03-01

DOI: 10.1002/mds.22879PMID: 20155864